Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

Published:2012-02 Issue:2 Volume:13 Page:154-162
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gotlieb Walter H,Amant Frederic,Advani Suresh,Goswami Chanchal,Hirte Hal,Provencher Diane,Somani Naresh,Yamada S Diane,Tamby Jean-Francois,Vergote Ignace

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer;Gotlieb;Gynecol Oncol,1998

2. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial;Heiss;Int J Cancer,2010

3. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model;Hu;Clin Cancer Res,2005

4. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease;Kraft;Cancer,1999

5. Biology of vascular endothelial growth factors;Roy;FEBS Lett,2006

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study;Molecular Therapy;2024-06

2. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

3. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial;Translational Oncology;2024-05

4. Malignant ascites: Current therapy options and treatment prospects;Cancer Treatment Reviews;2023-12

5. Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap;Expert Opinion on Therapeutic Targets;2023-09-02